Novartis readies first smart pill app

After investing $24 million earlier this year to gain access to cutting-edge smart pill technology, Novartis ($NVS) says it is 18 months away from filing for approval of its first chip-in-a-pill offering. The chips broadcast information to a skin patch, which in turn relays the information via smart phone. The first application will center on proper dosing for an approved drug that is used to prevent organ rejection among transplant patients. And because it is an existing drug, Novartis says that it only needs to prove bioequivalency rather than sponsor new clinical trials. Story

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.